A private prescription for a GLP-1 medicine should follow a careful clinical assessment—not a checkout form, a quick photo review or a promise of fast weight loss. The prescriber needs to check whether treatment is appropriate for you, explain its risks and practical demands, and plan how your health and progress will be reviewed.
GLP-1 medicines can help some people manage weight, but they are not suitable foundayo orforglipron for everyone and do not replace ongoing care. Weight is influenced by biology, health, medicines, environment and life circumstances—not simply willpower. A responsible provider treats you without blame and makes decisions based on your health, the medicine’s authorised use and your preferences.
First, understand what the medicine does
GLP-1 stands for glucagon-like peptide-1, a hormone involved in regulating blood sugar, digestion and appetite. GLP-1 medicines act on receptors for this hormone, helping the body release insulin when needed, slowing how quickly the stomach empties and increasing feelings of fullness.
Satiety means the feeling of being comfortably full after eating. By strengthening satiety signals, a GLP-1 medicine may help some people feel satisfied with less food or have fewer persistent thoughts about eating, sometimes called “food noise.” That mental load can be tiring; reduced appetite or fewer food preoccupations may be helpful, but the effect varies and is not guaranteed.
These medicines do not make someone’s choices effortless or address every reason for weight gain. A good provider will discuss nutrition, physical activity, sleep, emotional wellbeing and other health needs without implying that weight is a moral failing.
Check the medicine and the MHRA approval pathway
The MHRA, or Medicines and Healthcare products Regulatory Agency, is the UK body that assesses and regulates medicines. A legitimate provider should identify the exact medicine being offered, explain whether it is authorised by the MHRA for the proposed use, and provide clear information about its benefits, risks and limits.
Authorisation is medicine-specific: a product being authorised for one condition does not automatically mean it is authorised for weight management. For example, different GLP-1 medicines and formulations can have different approved uses. Ask the provider to tell you the medicine’s name, formulation and intended indication, and to explain any use outside its authorised indication. Prescribing outside an authorised indication is sometimes called off-label prescribing; it requires a clear clinical rationale and an informed discussion, not vague assurances.
Also distinguish medicine approval from provider legitimacy. MHRA authorisation does not, by itself, confirm that a website or clinic is safe. In Scotland, check that the dispensing pharmacy is registered with the General Pharmaceutical Council (GPhC), and check the professional registration of the prescriber. The provider should make it easy to find these details, along with a real contact route for clinical questions.
A clinical assessment is required—not just an online questionnaire
A clinical assessment is a review by an appropriately qualified prescriber to decide whether a treatment is safe and suitable for an individual. For private GLP-1 treatment, it should happen before the first prescription, whether the appointment is face-to-face or remote.
A responsible prescriber should ask about your health, treatment goals and circumstances, then explain how that information affects the decision. The assessment should include, as appropriate:
- Your current weight and height, and your body mass index (BMI). BMI is a screening measure calculated from weight and height; it is useful in some decisions but does not describe a person’s overall health on its own. Weight-related conditions, such as type 2 diabetes, high blood pressure or sleep apnoea. Current and recent medicines, including other weight-loss medicines and medicines for diabetes. Relevant medical history, including past problems with the pancreas or gallbladder, significant digestive symptoms and any allergies. Pregnancy, breastfeeding or plans to become pregnant, where relevant. Weight-management GLP-1 medicines are generally not used during pregnancy; the prescriber should explain the product-specific advice and timing for stopping before a planned pregnancy. Eating patterns, mental wellbeing and any history that could affect safe treatment or the support you may need.
This list is not a substitute for a clinician’s judgement. The prescriber should ask follow-up questions when something needs clarification, rather than treating a tick-box answer as a complete assessment.
Confirm BMI criteria and explain what they mean
To confirm BMI criteria means checking whether a person meets the weight and health thresholds for the specific medicine and indication. The provider should record your height and weight, calculate your BMI and explain how the relevant criteria apply to you.
For several UK-authorised medicines used for weight management, the licensed adult criteria generally include a BMI of at least 30, or at least 27 with a weight-related health condition. Exact criteria can differ by product, age group and indication, and may change as authorisations are updated. A provider should check the current product information rather than rely on a generic website rule.
Do not confuse eligibility for a private prescription with eligibility for NHS treatment. NHS access may be subject to additional national guidance, local pathways and service availability. Conversely, being eligible under a product’s licence does not mean the medicine is automatically right for you. The prescriber still needs to assess safety, likely benefit and your preferences.
Talk through risks, side effects and when to get help
A side effect is an unwanted effect that can happen while taking a medicine. Common effects of GLP-1 medicines include nausea, diarrhoea, constipation and vomiting, particularly when starting treatment or increasing the dose. A provider should explain how dose increases are scheduled, what to do if symptoms occur and when symptoms need urgent medical attention.
Rare but serious problems may also need discussion, including inflammation of the pancreas or gallbladder complications. The prescriber should explain warning signs and give you a clear route to medical advice. They should also review other medicines: for example, changes in food intake or blood glucose can affect the management of diabetes, and some people may need closer monitoring or dose adjustments to other medicines.
You should be able to ask questions without being rushed. Before prescribing, the provider should make sure you understand the expected benefits, uncertainties, possible harms, alternatives and what happens if you decide not to proceed.
Set a plan to monitor progress
Monitoring means checking how treatment is affecting your health and whether it remains appropriate. A legitimate provider should agree a follow-up plan before prescribing, not leave you to manage dose changes and side effects alone.
The plan should say who will contact you, how often reviews will happen and how to get help between appointments. It should cover both benefit and safety—not just the number on the scale. Depending on your health and treatment, reviews may include weight, side effects, appetite, eating patterns, blood glucose or other relevant measures.
Stage What a safe provider should do Before the first dose Complete the clinical assessment, confirm eligibility, review relevant medicines and health history, and explain the treatment plan. During dose increases Explain the schedule, check how you are tolerating treatment and advise what to do if a dose is missed or side effects develop. At regular reviews Monitor progress and wellbeing, revisit risks and benefits, and adjust or stop treatment when clinically appropriate. If treatment ends Discuss a safe stopping plan and ongoing support, including the possibility that appetite or weight may change after stopping.Ask how soon the first follow-up will take place and how frequently reviews continue. The exact schedule depends on the medicine, dose and your health; “we’ll check in sometime” is not a monitoring plan. A provider should also explain what counts as a reason to pause treatment or arrange a medical review.
Ask carefully about oral GLP-1 access and convenience
An oral medicine is taken by mouth, while an injectable medicine is delivered under the skin using a pen or syringe. People may prefer tablets, but oral and injectable products are not automatically interchangeable: they can have different ingredients, doses, approved uses and instructions.
Before accepting an offer of an oral GLP-1 product for weight loss, ask whether that exact formulation is currently authorised by the MHRA for weight management. Some oral GLP-1 medicines have been authorised for other conditions, such as type 2 diabetes, and that does not make them authorised weight-loss treatments. The provider should explain the distinction and the prescribing basis clearly.
Convenience also depends on how a tablet must be taken. Some oral products have specific instructions about timing, food or drink, and other medicines. A clinician or pharmacist should explain the instructions for your exact product and check that they fit your routine. Be cautious of websites that advertise “oral semaglutide” without naming the product, its authorised indication or the prescriber responsible.
Check dispensing, supply and ongoing support
The provider should tell you which registered pharmacy will dispense the medicine, how it will be stored and delivered, and whom to contact if a dose is delayed or a product arrives damaged. Medicines should come through a lawful, traceable supply chain—not social media sellers or informal marketplaces.
For injectable treatment, you should receive clear instructions on using and storing the pen, disposing of needles safely and what to do if you have trouble with an injection. A pharmacist should be available to answer practical questions. The provider should also be transparent about the total cost, including consultations, follow-up appointments, delivery and any fees for continued prescribing.
Warning signs of an unsafe provider
- They promise a particular amount of weight loss or describe the medicine as a miracle cure. They prescribe without a proper health history, a review of your medicines or a clear opportunity to speak with a clinician. They do not confirm BMI criteria or explain how the product’s eligibility rules apply to you. They offer a medicine without clearly naming its formulation, authorisation status or prescriber. They encourage rapid dose increases, dismiss significant side effects or provide no way to get clinical help. They make it difficult to identify the prescriber, pharmacy or relevant professional registrations. They frame treatment as a substitute for all other support or use shaming language about weight.
What to ask before you agree to treatment
Who will assess me and prescribe, and how can I verify their professional registration? Which exact medicine and formulation are you offering, and is it MHRA-authorised for this use? How will you confirm BMI criteria and assess my medical history and current medicines? What side effects should I expect, and what symptoms mean I should seek urgent help? When will you review me, what will you monitor, and how do I contact the clinical team? Which pharmacy dispenses the medicine, and what are the full costs of treatment and follow-up?The bottom line
A legitimate private GLP-1 provider should make a clinical assessment required in practice, confirm BMI criteria against the exact product’s current authorisation, explain risks and alternatives, and monitor progress through planned follow-up. They should also treat weight management as health care—not a test of character—and be straightforward about oral access, supply and ongoing support.
If a provider skips those steps or makes treatment sound effortless and risk-free, pause before paying or taking a dose. You can ask your GP or a registered pharmacist for advice about the medicine and how it fits with your wider care.